I Sadaf Farooqi Selected Research

Morbid Obesity

1/2022	Obesity Due to Steroid Receptor Coactivator-1 Deficiency Is Associated With Endocrine and Metabolic Abnormalities.
10/2021	Obesity-Associated GNAS Mutations and the Melanocortin Pathway.
1/2021	Monogenic human obesity syndromes.
1/2021	Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation.
12/2020	Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
1/2020	Leptin-Mediated Changes in the Human Metabolome.
11/2019	Crucial Role of the SH2B1 PH Domain for the Control of Energy Balance.
11/2018	Quantitative mass spectrometry for human melanocortin peptides in vitro and in vivo suggests prominent roles for β-MSH and desacetyl α-MSH in energy homeostasis.
1/2018	MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
11/2017	Disruption of the homeodomain transcription factor orthopedia homeobox (Otp) is associated with obesity and anxiety.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

I Sadaf Farooqi Research Topics

Disease

68	Obesity 01/2022 - 05/2002
25	Morbid Obesity 01/2022 - 08/2002
14	Weight Loss (Weight Reduction) 01/2022 - 01/2010
14	Hyperphagia (Overeating) 01/2022 - 12/2006
13	Body Weight (Weight, Body) 12/2019 - 05/2004
5	Insulin Resistance 11/2019 - 08/2005
5	Hypogonadism (Hypergonadotropic Hypogonadism) 09/2009 - 05/2002
4	Weight Gain 01/2022 - 11/2017
4	Adrenal Insufficiency (Adrenal Gland Hypofunction) 11/2018 - 08/2002
4	Hyperinsulinism (Hyperinsulinemia) 01/2011 - 10/2002
3	Pediatric Obesity 01/2020 - 10/2005
3	Overweight 10/2010 - 11/2008
2	Prader-Willi Syndrome (Syndrome, Prader-Willi) 01/2018 - 01/2003
2	Type 2 Diabetes Mellitus (MODY) 01/2017 - 01/2009
2	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 12/2006 - 09/2005
2	Hyperlipidemias (Hyperlipidemia) 10/2004 - 10/2002
1	Pseudohypoparathyroidism 10/2021
1	Neurobehavioral Manifestations 01/2021
1	Hyperpigmentation 12/2020
1	Vomiting 12/2020
1	Injection Site Reaction 12/2020
1	Nausea 12/2020
1	Frontotemporal Dementia (Semantic Dementia) 01/2018
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2018
1	Apnea 09/2016
1	Sarcoma (Soft Tissue Sarcoma) 09/2014
1	Retinal Dystrophies 03/2014
1	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 09/2013
1	Adenoma (Adenomas) 09/2013
1	Hypertension (High Blood Pressure) 09/2013
1	Bulimia (Binge Eating) 05/2013
1	Hypothyroidism 01/2012
1	Constipation 01/2012
1	Thyroid Hormone Resistance Syndrome (Thyroid Hormone Resistance) 01/2012
1	Kallmann Syndrome (Kallmann's Syndrome) 10/2011
1	Diabetes Insipidus 10/2011
1	Communicable Diseases (Infectious Diseases) 04/2010
1	Sepsis (Septicemia) 04/2010

Drug/Important Bio-Agent (IBA)

21	LeptinIBA 01/2021 - 05/2002
16	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 01/2022 - 03/2003
14	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2002
11	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 01/2021 - 08/2002
10	MelanocortinsIBA 01/2022 - 08/2002
7	Leptin ReceptorsIBA 01/2021 - 05/2002
6	Insulin (Novolin)FDA Link 01/2022 - 01/2003
5	Hormones (Hormone)IBA 01/2022 - 05/2002
5	Peptides (Polypeptides)IBA 12/2019 - 01/2007
4	LigandsIBA 01/2021 - 01/2003
4	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 09/2007
3	Biological ProductsIBA 01/2022 - 09/2005
3	setmelanotideIBA 12/2020 - 10/2017
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020 - 12/2006
3	Proprotein Convertase 1IBA 09/2013 - 11/2003
2	ArrestinIBA 01/2021 - 01/2019
2	Oxytocin (Pitocin)FDA LinkGeneric 11/2017 - 01/2017
2	Protein Isoforms (Isoforms)IBA 09/2014 - 10/2004
2	Thyroid HormonesIBA 01/2012 - 04/2010
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 10/2010 - 01/2009
2	EnzymesIBA 09/2007 - 11/2003
1	CarbohydratesIBA 01/2022
1	Steroid Receptors (Steroid Receptor)IBA 01/2022
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2022
1	Troleandomycin (TAO)FDA Link 11/2021
1	Dietary Fats (Dietary Fat)IBA 01/2021
1	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 01/2020
1	Appetite Depressants (Anorectics)IBA 12/2019
1	platelet protein P47 (pleckstrin)IBA 11/2019
1	Neuropilin-2IBA 01/2019
1	P-2 (P 2)IBA 01/2019
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2018
1	LipidsIBA 01/2018
1	Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA 11/2017
1	Transcription Factors (Transcription Factor)IBA 11/2017
1	Arginine Vasopressin (Argipressin)IBA 11/2017
1	Pharmaceutical PreparationsIBA 01/2017
1	Amino Acids FDA Link 09/2015
1	AldosteroneIBA 09/2013
1	Vasopressins (Vasopressin)IBA 09/2013
1	Adenosine Monophosphate (AMP)IBA 07/2013
1	Type 2 Melanocortin ReceptorIBA 07/2013
1	mu Opioid Receptors (mu Opioid Receptor)IBA 05/2013
1	Opioid Analgesics (Opioids)IBA 05/2013
1	N- ((3,5- difluoro- 3'- (1H- 1,2,4- triazol- 3- yl)- 4- biphenylyl)methyl)- 2,3- dihydro- 1H- inden- 2- amineIBA 05/2013
1	Adrenocorticotropic Hormone (ACTH)FDA Link 10/2011
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2011
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 10/2011
1	Growth Hormone (Somatotropin)IBA 01/2011
1	sibutramine (Meridia)FDA Link 10/2010
1	Serotonin (5 Hydroxytryptamine)IBA 10/2010
1	Anti-Obesity Agents (Antiobesity Drugs)IBA 10/2010
1	Blood Glucose (Blood Sugar)IBA 01/2010
1	CatecholaminesIBA 01/2009

Therapy/Procedure

14	Therapeutics 01/2022 - 09/2003
2	Caloric Restriction 12/2017 - 09/2016
1	Aftercare (After-Treatment) 01/2020
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 06/2012
1	Ligation 04/2010
1	Punctures 04/2010